Blog

Anecdotes versus Evidence: Validating the Diagnosis Process

Posted by: Michaela Gascon and Jessica Spilman on 3/14/2019

How long does it take to ascertain the correct diagnosis? Which doctors will patients see, and who will they be referred to next? These seemingly direct questions are often all too complicated in rare disease. If we could better educate providers about disease symptoms and triggers, perhaps patients could be diagnosed sooner, and begin appropriate treatment sooner as well. That’s exactly what the International Pemphigoid and Pemphigus Foundation (IPPF) had in mind. Read the full post to learn how we helped!


Read Full Post

Tags: Patient Journey | Rare Disease | Orphan Disease
Related Posts: Winter 2019

What is Patient Journey?

Posted by: Amy Allen and Michelle Soto on 2/28/2019

What is patient journey? There is often overlap and sometimes interchangeable terminology among patient journey, patient flow through the healthcare system, and the treatment buying process. In rare diseases, the patient journey can be even more critical, as there may be a lack of internal knowledge, published data, or even currently available treatments. Read the full post to learn more!


Read Full Post

Tags: Patient Journey | Rare Disease | Orphan Disease
Related Posts: Winter 2019

The New Market Segmentation – Increasing Treatment Duration Through Market Interventions

Posted by: Craig Radley on 2/6/2019

We’ve all heard the business adage that acquiring a new customer costs 6 – 7 times as much as retaining an existing one. But how often is that wisdom applied for pharmaceutical products? As an industry, we are often too focused on driving new patient prescriptions and forget to focus on the patients already taking our product. Average treatment duration is one of the most important metrics in evaluating sales of a pharmaceutical product and small improvements translate directly to a product’s bottom-line. Read the full post to learn more!


Read Full Post

Tags: Segmentation | Treatment Duration | Pharmaceuticals
Related Posts: Fall 2018

Leveraging Virtual Voice-Response Interviews for Diabetes Panel Concept Testing

Posted by: Jess Spilman and Corinne Shanahan on 1/10/2019

One of our longtime clients recently engaged with us to collect physician feedback on two diabetes-related diagnostic testing panels. Because rollout was impending, rapid insights were needed to inform their decision. To obtain nuanced information quickly, we employed a new methodology called Virtual Voice-response Interviews (VVIs). Read the full post to learn more!


Read Full Post

Tags: Virtual Voice-response Interviews | Diabetes | Endocrinology
Related Posts: Fall 2018

Using Allocation Exercises to Inform Clinical Trial Design

Posted by: Jonny Davis on 12/18/2018

Clinical trials are a significant portion of the cost to bring a new drug to market. Recent research published in Clinical Trials estimated the combined average total cost of conducting a single endocrinology clinical trial in each of Phases I, II, and III was US $30.5 million. With costs this high (and likely higher as time goes on), it’s natural to wonder if there are ways to optimize a clinical trial’s impact before committing to the substantial investment required. Fortunately, market research provides two opportunities to gauge the impact of a clinical trial through use of two designed experiment methodologies.


Read Full Post

Tags: Clinical trials | Pharmaceuticals | Endocrinology
Related Posts: Fall 2018

Looking for Value Below the Surface: Diabetes Management within Long-Term Care

Posted by: Dan Wasserman on 11/30/2018

An estimated 12 million Americans need some form of formal, long-term care (LTC). Commonly, when our clients think about the LTC market, they focus on skilled nursing facilities (SNFs), but assisted living facilities (ALFs) and home care are equally important for many products and services.


Read Full Post

Tags: Skilled nursing facilities | Long-term care | Diabetes
Related Posts: Fall 2018